Compare Fox Corp Class A (FOXA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs TransMedics Group Inc — how do they compare? Fox Corp Class A trades at $63.64 (market cap $25.36B), while TransMedics Group Inc trades at $80.47 (market cap $2.74B). The key difference: Fox Corp Class A is far larger — about 9.3× TransMedics Group Inc's market cap, and Fox Corp Class A pays a 0.91% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and TransMedics Group Inc for 24 Days on average.
| FOXA | TMDX | |
|---|---|---|
Market Cap | $25.36B | $2.74B |
Volume | 2,566,954 | 949,331 |
Sector | Media | Health |
52-Week High | $76.11 | $150.42 |
52-Week Low | $48.79 | $61.99 |
Typical Hold Time | 34 Days | 24 Days |
Enterprise Value | $28.72B | $3.13B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $63.42, up 1.15% with a bullish technical signal and strong fundamental performance. The stock shows robust earnings momentum with three consecutive quarterly beats and solid profitability metrics including 14.29% ROE and 9.84% net margin. Recent news highlights the pending Roku acquisition and regulatory scrutiny, while institutional activity shows CEO Lachlan Murdoch's significant $10.3 million share purchase in September 2026.
The outlook remains positive with a $72 consensus price target representing 13.5% upside potential. Key opportunities include continued earnings growth and strategic acquisitions, while risks center on regulatory approval for the Roku deal and potential market volatility. With no analyst sell ratings and strong institutional support, FOXA presents a compelling investment case in the media sector.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
